Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR
JACC: Cardiovascular Interventions · 2025
DOI: 10.1016/j.jcin.2025.05.045 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Weiya Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Cardiac Structure and Function, Institute of Cardiov…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve, Bicuspid Aortic Valve Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program.
Abstract (Originalsprache)
BACKGROUND: Differences in long-term clinical outcomes following transcatheter aortic valve replacement (TAVR) in different anatomical subtypes of aortic valve stenosis (AS), specifically tricuspid aortic valves (TAV) and bicuspid aortic valves (BAV) of types 0 (BAV-0) and 1 (BAV-1), are not well understood. OBJECTIVES: The authors sought to report and compare the long-term clinical outcomes among patients with different anatomical subtypes of AS undergoing TAVR. METHODS: We conducted an international retrospective cohort study involving patients who underwent TAVR for severe AS at 3 large, high-volume heart centers in China, Germany, and Denmark before October 2018. Five-year follow-up ended on October 30, 2023, and the primary endpoint was all-cause mortality. RESULTS: A total of 2,553 AS patients (BAV-0: n = 134; BAV-1: n = 305; TAV: n = 2,114) who underwent TAVR more than 5 years ago were included. The mean age of this cohort was 79.9 ± 6.8 years, and the median Society of Thoracic Surgeons score was 3.6% [Q1-Q3: 2.4%-5.4%]. The median follow-up time was 3.24 years (Q1-Q3: 1.25-5.00 years). At 5 years, BAV-1 (adjusted HR: 2.38 [95% CI: 1.32-4.28]; P = 0.004) and TAV (adjusted HR: 3.02 [95% CI: 1.71-5.31]; P < 0.001) had a higher risk for all-cause mortality after TAVR compared with BAV-0. BAV patients who were treated with balloon-expandable valves had a higher long-term all-cause mortality (41.7% [28.5%-52.5%] vs 23.6% [17.9%-28.8%]; HR: 1.63 [95% CI: 1.05-2.51]; P = 0.028) compared with those with self-expanding valves. CONCLUSIONS: Among patients with severe AS undergoing TAVR, BAV-0 was associated with a better long-term prognosis compared with TAV and BAV-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, Ch…
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China; Cardiac Structure and Function Research Key Laboratory of Sichuan Province, We…
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Förderung
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Li, W., Jia, Y., Li, H., Kobari, Y., Li, J., Feng, Y., Peng, Y., Wei, J., Zhao, Z., Xiong, T., Yang, H., Song, C., Lei, W., Peng, S., Yin, Y., Qiao, X., Wang, D., Kim, W. K., De Backer, O., & Chen, M. (2025). Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.05.045
Vancouver
Li W, Jia Y, Li H, Kobari Y, Li J, Feng Y, et al. Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.05.045
BibTeX
@article{Li2025,
author = {Li, Weiya and Jia, Yuheng and Li, Hongde and Kobari, Yusuke and Li, Junli and Feng, Yuan and Peng, Yong and Wei, Jiafu and Zhao, Zhengang and Xiong, Tianyuan and Yang, Haoran and Song, Chengxiang and Lei, Wenhua and Peng, Shiqin and Yin, Yue and Qiao, Xuechen and Wang, Duolao and Kim, Won-Keun and De Backer, Ole and Chen, Mao},
title = {Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
doi = {10.1016/j.jcin.2025.05.045}
}
EUVIMED